GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk
Obesity Reviews · 2026-04 · 27 (4)
DOI: 10.1111/obr.70049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity Reviews, online erschienen am 03.12.2025. Verfasst von Hiba Jebeile und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Feeding and Eating Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 85 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
This rapid review aimed to evaluate the effects of GLP‐1 RAs on eating behaviors and eating disorder risk. Databases were searched to January 2025 to identify studies evaluating GLP‐1 RA treatment for adolescents or adults with obesity or Type 2 diabetes. Eligible studies reported adverse events, changes in eating disorder risk, or eating behaviors post‐intervention or follow‐up. Data were synthesized narratively. Of 1597 records screened, 25 studies (k) were included (two adolescent, n = 275; 23 adult, n = 8722). Two studies reported eating disorder adverse events, and two reported no binge eating adverse events. Liraglutide reduced global eating disorder risk scores, with no differences between groups (k = 1). Binge eating episodes and prevalence reduced following liraglutide and semaglutide, respectively. Binge eating scores improved with liraglutide compared to placebo (k = 2). Food cravings following liraglutide (k = 1) or semaglutide (k = 6) were improved (k = 6) or unchanged (k = 1). There was no difference in disinhibition between liraglutide and comparator (k = 2) with one study reporting a reduction in both groups. Three non‐RCTs reported reduced disinhibition with liraglutide. Limited data are available on GLP‐1 RAs, eating behaviors and eating disorders. For most, eating behaviors may improve or remain unchanged. Comprehensive assessment of eating behaviors is needed to understand the benefits and risks of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
- Charles Perkins Centre, The University of Sydney, Sydney, Australia.
- Department of Clinical Psychology, University of Bergen, Bergen, Norway.
- Regional Department of Eating Disorders, Haukeland University Hospital, Bergen, Norway.
- Department of Surgery, School of Translational Medicine, Monash University, Melbourne, Australia.
- Department of Endocrinology and Diabetes, Alfred Health, Melbourne, Australia.
ORCID-Profile: Hiba Jebeile, Yngvild Sørebø Danielsen, Priya Sumithran, Louise A Baur, Natalie B Lister
Zitieren
APA
Jebeile, H., Danielsen, Y. S., Sumithran, P., Lorien, S., Jardine, I. R., Baur, L. A., & Lister, N. B. (2026). GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk. Obesity Reviews, 27(4). https://doi.org/10.1111/obr.70049
Vancouver
Jebeile H, Danielsen YS, Sumithran P, Lorien S, Jardine IR, Baur LA, et al. GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk. Obesity Reviews. 2026;27(4). doi:10.1111/obr.70049
BibTeX
@article{Jebeile2026,
author = {Jebeile, Hiba and Danielsen, Yngvild Sørebø and Sumithran, Priya and Lorien, Sasha and Jardine, Isabelle R and Baur, Louise A and Lister, Natalie B},
title = {GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk},
journal = {Obesity Reviews},
year = {2026},
volume = {27},
number = {4},
doi = {10.1111/obr.70049}
}
EUVIMED